बुल्गारिया - बुल्गारियाई - Изпълнителна агенция по лекарствата

hikma farmaceutica (portugal), s.a. - ciprofloxacin - 250 mg film - coated tablets

बुल्गारिया - बुल्गारियाई - Изпълнителна агенция по лекарствата

hikma farmaceutica (portugal), s.a. - ciprofloxacin - 500 mg film - coated tablets

बुल्गारिया - बुल्गारियाई - Изпълнителна агенция по лекарствата

hikma farmaceutica (portugal), s.a. - ciprofloxacin - 750 mg film - coated tablets

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

laboratorios hipra s.a. - жива аттенуированная респираторно-синцитиальный вирус от едър рогат добитък (brsv), прецедете Лым-56 - Имуномодулатори за бичи, говеда, живи вирусни ваксини, бичи респираторно-синцитиальный вирус (brsv) - Говеда - Активна имунизация на едрия рогат добитък, за да се намали отделянето на вируса и респираторни клинични признаци, причинена от респираторно-синцитиальной инфекция на едър рогат добитък .

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - Прасета - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

laboratorios hipra, s.a. - clostridioides difficile toxoid a, clostridioides difficile toxoid b, clostridium perfringens, type a, alpha toxoid - immunologicals for suidae, inactivated bacterial vaccines for pigs, clostridium - Прасета - for the passive immunisation of neonatal piglets by means of the active immunisation of breeding sows and gilts:- to prevent mortality and reduce clinical signs and macroscopic lesions caused by clostridioides difficile toxins a and b. - to reduce clinical signs and macroscopic lesions caused by clostridium perfringens type a, alpha toxin.

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

bayer animal health gmbh  - прадофлоксацин - Антибактериални средства за подаване на заявления, фторхинолоны - dogs; cats - dogstreatment от:раневых на инфекции, причинени от чувствителни щамове на staphylococcus Интер Групи (включително. pseudintermedius);повърхностни и дълбоки пиодермии, причинени от чувствителни щамове на staphylococcus Интер Групи (включително. pseudintermedius);остри инфекции на пикочните пътища, причинени от чувствителни щамове на escherichia coli и staphylococcus Интер Групи (включително. pseudintermedius);като допълнителна терапия към механично или хирургическа пародонтологического лечение при лечение на тежки инфекции на венците и околозубных на тъканите, причинени от чувствителни щамове на анаеробни организми, например, porphyromonas). и prevotella spp. catstreatment остри инфекции на горните дихателни пътища, причинени от чувствителни щамове на бактерии, pasteurella multocida, escherichia coli и staphylococcus Интер Групи (включително. pseudintermedius).

बुल्गारिया - बुल्गारियाई - Изпълнителна агенция по лекарствата

stallergenes s.a. - Животни - allergen extract from animal origin, solution for skin-prick test

यूरोपीय संघ - बुल्गारियाई - EMA (European Medicines Agency)

janssen-cilag international nv - ibrutinib - lymphoma, mantle-cell; leukemia, lymphocytic, chronic, b-cell - antineoplastic agents, protein kinase inhibitors - imbruvica as a single agent is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (mcl). imbruvica as a single agent or in combination with rituximab or obinutuzumab or venetoclax is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. imbruvica as a single agent or in combination with bendamustine and rituximab (br) is indicated for the treatment of adult patients with cll who have received at least one prior therapy. imbruvica as a single agent is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo immunotherapy. imbruvica in combination with rituximab is indicated for the treatment of adult patients with wm.

बुल्गारिया - बुल्गारियाई - БАБХ (Българска агенция по безопасност на храните)

divasa-farmavic s.a. - penethamate хидрохлорид - прах и разтворител за инжекционна суспензия - 236, 3 mg/ml - говеда